Market Outlook

The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Medivation/Astellas Pharma). These targeted therapies have benefited efficacy outcome and offer favorable safety profiles. The management of mCRPC has been further transformed with the availability of therapeutic vaccine Provenge (Valeant) and radiopharmaceutical agent Xofigo (Bayer HealthCare). Nevertheless, an enormous  unmet need exists for better-tolerated novel therapies that could prolong overall survival and, to a greater extent, delay disease progression. Our unmet need module analyzes the key drivers of prescribing and identifies the most attractive commercial opportunities for drug developers.

Questions Answered

  • What are the treatment drivers and goals for mCRPC?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
  • How do current therapies perform on key treatment drivers and goals for mCRPC?
  • What are the prevailing areas of unmet need and opportunity in mCRPC?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new first-line mCRPC therapy?

Product Description

Unmet Need provides quantitative insight into U.S. and European physicians’ perception of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, and the United Kingdom.

Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in August 2018.

Key companies:  Johnson & Johnson/Janssen, Medivation/Astellas, Valeant, Bayer HealthCare, and Sanofi.

Key drugs: Zytiga, Xtandi, Provenge, Xofigo, and Jevtana.

Table of contents

  • Prostate Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
        • Products for Metastatic Castrate-Resistant Prostate Cancer
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer
      • Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Metastatic Castrate-Resistant Prostate Cancer: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer: United States
      • Overall Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes: United States
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Safety and Tolerability Attributes: Europe
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Metastatic Castrate-Resistant Prostate Cancer
      • Surveyed Medical Oncologists’ Satisfaction with the Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Medical Oncologists’ Satisfaction with the Performance of Key Therapies for Metastatic Castrate-Resistant Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Castrate-Resistant Prostate Cancer: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Metastatic Castrate-Resistant Prostate Cancer: Europe
      • Key Findings: Unmet Need in Metastatic Castrate-Resistant Prostate Cancer and Related Indications
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Castrate-Resistant Prostate Cancer and Related Indications: United States
      • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Metastatic Castrate-Resistant Prostate Cancer and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Metastatic Castrate-Resistant Prostate Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Overall Survival
        • Opportunity: A New Therapy That Delays Disease Progression
        • Opportunity: A New Therapy That Can Improve Bone Metastases-Related Pain
        • Opportunity: A New Therapy with Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile: Attribute Importance
        • Median Overall Survival
        • Median Radiographic Progression-Free Survival
        • PSA Response Rate
        • Incidence of Grade 3/4 Gastrointestinal Toxicity
        • Incidence of Grade 3/4 Cardiovascular Toxicity
        • Discontinuations Due to Adverse Events
        • Price per Course of Treatment
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 1
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.


Related Reports

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx fo...

View Details

Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details